Cognition Therapeutics Closes $2.5M Series A1 Financing

Cognition Therapeutics, Inc., a Pittsburgh, PA-based drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer’s, has closed on a $2.5m Series A1 financing.
The round was led by Golden Seeds, with participation from new investors The Breedlove Limited Family Partnership and TMC Investment Company, and existing investors Ogden CAP Associates, M5Invest, the Pittsburgh Life Sciences Greenhouse and Innovation Works.
The financing, which was comprised of new investment and conversion of convertible debt, was syndicated with Tech Coast Angels
The company intends to use the funds to bring its compounds to Investigational New Drug (IND) candidate status.
Led by President and CEO Hank Safferstein, Ph.D., J.D., Cognition has developed a number of screening strategies to identify small molecules capable of blocking the central toxicity of proteins in Alzheimer’s disease and other neurodegenerative diseases.
In conjunction with the transaction, Dr. Nada Jain, Managing Director of Golden Seeds and Mr. Mark Breedlove, President and CEO of Keystone Profiles, have joined the company’s board of directors.


Join the discussion